Insufficient yellow fever vaccine stocks in Africa

December 20, 2001

N.B Please note that if you are outside North America the embargo date for Lancet Press Material is 0001 hours UK time Friday 21st December 2001.

A research letter in this week's issue of THE LANCET which describes a recent yellow fever outbreak in Guinea, Africa, highlights that there are insufficient stocks of yellow fever vaccine to cope with future outbreaks of the disease.

Yellow fever is a viral haemorrhagic fever that is caused by a flavivirus transmitted by mosquitoes. Case fatality ratios (CFR) exceed 50% in severe instances. The disease can be prevented by vaccination with the 17D yellow fever vaccine, which protects for at least 10 years. WHO estimates that 200 000 people in 34 endemo-epidemic countries of Africa and America are infected with the disease every year, resulting in 30 000 deaths.

Nicolas Nathan from Epicentre, Paris, France, and colleagues from the Guinean Department of Health describe a yellow fever epidemic that erupted in Guinea in September, 2000. A mass vaccination campaign was limited by insufficient international stocks. After the epidemic in Guinea, the International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control decided that 2 million doses of 17D yellow fever vaccine, being stored as part of a UNICEF stockpile, should be used only in response to yellow fever outbreaks.

Nicolas Nathan comments: "Yellow fever epidemics are re-emerging in Africa and America, and the occurrence of repeated rural outbreaks increases the risk for major urban epidemics. However, as shown by the Guinean episode, the international stocks of yellow fever vaccines are not sufficient to provide an adequate and rapid response to large outbreaks. In 2000, an alert was sounded in Kano city (1.5 million inhabitants), Nigeria. No epidemic occurred, but had there been one the stocks of vaccines would not have been adequate. During the yellow fever consensus meeting, WHO recommended that an emergency stockpile of 1 million doses be retained in Africa and America for outbreak response.
-end-
Contact: Dr Nicolas Nathan, Epicentre, 75011 Paris, France; T) +33 1 40 21 28 48; f) +33 1 40 21 28 03; E) nnathan@epicentre.msf.org

Lancet

Related Vaccines Articles from Brightsurf:

Comprehensive safety testing of COVID-19 vaccines based on experience with prior vaccines
'The urgent need for COVID-19 vaccines must be balanced with the imperative of ensuring safety and public confidence in vaccines by following the established clinical safety testing protocols throughout vaccine development, including both pre- and post-deployment,' write David M.

Safety of HPV vaccines in males
A new analysis published in the British Journal of Clinical Pharmacology shows that HPV vaccines are safe and well tolerated in the male population, and the side effects that may occur after immunization are similar in both sexes.

Model could improve design of vaccines, immunotherapies
Researchers have discovered a general property for understanding how immune cell receptors sense and respond to microbial signals, which could lead to more effective vaccines for both existing and novel viruses.

Better vaccines are in our blood
Red blood cells don't just shuttle oxygen from our lungs to our organs: they also help the body fight off infections by capturing pathogens in the blood and presenting them to immune cells in the spleen.

Challenges in evaluating SARS-CoV-2 vaccines
With more than 140 SARS-CoV-2 vaccines in development, the race is on for a successful candidate to help prevent COVID-19.

Designing vaccines from artificial proteins
EPFL scientists have developed a new computational approach to create artificial proteins, which showed promising results in vivo as functional vaccines.

Misinformation on vaccines readily available online
Parents researching childhood vaccinations online are likely to encounter significant levels of negative information, researchers at the University of Otago, Wellington, have found.

Battle with the cancer: New avenues from childhood vaccines
A new research from the University of Helsinki showed for the first time how the pre-immunization acquired through common childhood vaccines can be used to enhance therapeutic cancer treatment.

Personalized cancer vaccines
The only therapeutic cancer vaccine available on the market has so far showed very limited efficacy in clinical trials.

Doubts raised about effectiveness of HPV vaccines
A new analysis of the clinical trials of HPV vaccines to prevent cervical cancer raises doubts about the vaccines' effectiveness.

Read More: Vaccines News and Vaccines Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.